{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:05:24Z","timestamp":1762459524365},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/bmt.2017.95","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T13:41:33Z","timestamp":1496670093000},"page":"1304-1310","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention"],"prefix":"10.1038","volume":"52","author":[{"given":"Z","family":"Al-Kadhimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Abidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L G","family":"Lum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Deol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ozust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Langston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Uberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"BFbmt201795_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/0002-9343(79)91171-9","volume":"66","author":"PR Graze","year":"1979","unstructured":"Graze PR, Gale RP . Chronic graft versus host disease: a syndrome of disordered immunity. Am J Med 1979; 66: 611\u2013620.","journal-title":"Am J Med"},{"key":"BFbmt201795_CR2","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487\u20131496.","journal-title":"N Engl J Med"},{"key":"BFbmt201795_CR3","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","volume":"117","author":"G Socie","year":"2011","unstructured":"Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011; 117: 6375\u20136382.","journal-title":"Blood"},{"key":"BFbmt201795_CR4","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","volume":"29","author":"JR Wingard","year":"2011","unstructured":"Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230\u20132239.","journal-title":"J Clin Oncol"},{"key":"BFbmt201795_CR5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","volume":"21","author":"M Boyiadzis","year":"2015","unstructured":"Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res 2015; 21: 2020\u20132028.","journal-title":"Clin Cancer Res"},{"key":"BFbmt201795_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199907013410103","volume":"341","author":"G Socie","year":"1999","unstructured":"Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14\u201321.","journal-title":"N Engl J Med"},{"key":"BFbmt201795_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.bbmt.2014.01.010","volume":"20","author":"JH Moon","year":"2014","unstructured":"Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J et al. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transplant 2014; 20: 556\u2013563.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3109\/10428194.2013.820285","volume":"55","author":"C Saillard","year":"2014","unstructured":"Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A et al. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma 2014; 55: 1106\u20131112.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201795_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2008.07.015","volume":"14","author":"JA Perez-Simon","year":"2008","unstructured":"Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo FM et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant 2008; 14: 1163\u20131171.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555\u2013562.","journal-title":"Blood"},{"key":"BFbmt201795_CR12","first-page":"921","volume":"18","author":"O Ringden","year":"1996","unstructured":"Ringden O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 18: 921\u2013929.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201795_CR13","first-page":"248","volume":"13","author":"PL Weiden","year":"1981","unstructured":"Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED . Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981; 13: 248\u2013251.","journal-title":"Transplant Proc"},{"key":"BFbmt201795_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1586\/ehm.11.39","volume":"4","author":"S Bhatia","year":"2011","unstructured":"Bhatia S . Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 2011; 4: 437\u2013452 quiz 453-434.","journal-title":"Expert Rev Hematol"},{"key":"BFbmt201795_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/bmt.2009.238","volume":"45","author":"SA Mitchell","year":"2010","unstructured":"Mitchell SA, Leidy NK, Mooney KH, Dudley WN, Beck SL, LaStayo PC et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 2010; 45: 762\u2013769.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201795_CR16","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood.V75.12.2459.2459","volume":"75","author":"K Atkinson","year":"1990","unstructured":"Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459\u20132464.","journal-title":"Blood"},{"key":"BFbmt201795_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","volume":"21","author":"S Arai","year":"2015","unstructured":"Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015; 21: 266\u2013274.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","volume":"10","author":"C Cutler","year":"2004","unstructured":"Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 328\u2013336.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR19","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","volume":"109","author":"C Cutler","year":"2007","unstructured":"Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108\u20133114.","journal-title":"Blood"},{"key":"BFbmt201795_CR20","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","volume":"124","author":"C Cutler","year":"2014","unstructured":"Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D et al. Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014; 124: 1372\u20131377.","journal-title":"Blood"},{"key":"BFbmt201795_CR21","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942\u20132947.","journal-title":"Blood"},{"key":"BFbmt201795_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","volume":"12","author":"A Bacigalupo","year":"2006","unstructured":"Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560\u2013565.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 2016; 374: 43\u201353.","journal-title":"N Engl J Med"},{"key":"BFbmt201795_CR24","volume-title":"A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Tra","author":"J Robert","year":"2016","unstructured":"Robert J, Soiffer M, Haesook TK, McGuirk J, Horwitz ME, Johnston L et al. A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT), In: American Society of Hematology: San Diego, CA, 2016."},{"key":"BFbmt201795_CR25","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.bbmt.2012.06.004","volume":"18","author":"Z Al-Kadhimi","year":"2012","unstructured":"Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A et al. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1734\u20131744.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR26","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995 15: 825\u2013828."},{"key":"BFbmt201795_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.bbmt.2014.03.016","volume":"20","author":"Z Al-Kadhimi","year":"2014","unstructured":"Al-Kadhimi Z, Gul Z, Chen W, Smith D, Abidi M, Deol A et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biol Blood Marrow Transplant 2014; 20: 979\u2013985.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR28","first-page":"2062","volume":"96","author":"RA Nash","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062\u20132068.","journal-title":"Blood"},{"key":"BFbmt201795_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","volume":"19","author":"S Shayani","year":"2013","unstructured":"Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, Khuu T et al. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2013; 19: 298\u2013304.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR30","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","volume":"118","author":"AH Elmaagacli","year":"2011","unstructured":"Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118: 1402\u20131412.","journal-title":"Blood"},{"key":"BFbmt201795_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1600-0609.1987.tb00010.x","volume":"38","author":"N Jacobsen","year":"1987","unstructured":"Jacobsen N, Lonnqvist B, Ringden O, Rajantie J, Siimes MA, Volin L et al. Graft-versus-leukaemia activity associated with cytomegalovirus seropositive bone marrow donors but separated from graft-versus-host disease in allograft recipients with AML. Eur J Haematol 1987; 38: 350\u2013355.","journal-title":"Eur J Haematol"},{"key":"BFbmt201795_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbmt.2008.10.023","volume":"15","author":"CE Behrendt","year":"2009","unstructured":"Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ . Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009; 15: 54\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1600-0609.2005.00625.x","volume":"76","author":"D Nachbaur","year":"2006","unstructured":"Nachbaur D, Clausen J, Kircher B . Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 2006; 76: 414\u2013419.","journal-title":"Eur J Haematol"},{"key":"BFbmt201795_CR34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3109\/14653249.2012.715243","volume":"14","author":"M Bosch","year":"2012","unstructured":"Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012; 14: 1258\u20131275.","journal-title":"Cytotherapy"},{"key":"BFbmt201795_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.bbmt.2014.11.681","volume":"21","author":"C Pical-Izard","year":"2015","unstructured":"Pical-Izard C, Crocchiolo R, Granjeaud S, Kochbati E, Just-Landi S, Chabannon C et al. Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. Biol Blood Marrow Transplant 2015; 21: 429\u2013439.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201795_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.tp.0000296817.28053.7b","volume":"85","author":"LE Wai","year":"2008","unstructured":"Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM . Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008; 85: 145\u2013149.","journal-title":"Transplantation"},{"key":"BFbmt201795_CR37","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/bmt.2010.306","volume":"46","author":"L Buhlmann","year":"2011","unstructured":"Buhlmann L, Buser AS, Cantoni N, Gerull S, Tichelli A, Gratwohl A et al. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 1357\u20131362.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201795_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/bmt.2014.284","volume":"50","author":"Z Gul","year":"2015","unstructured":"Gul Z, Van Meter E, Abidi M, Ditah I, Abdul-Hussein M, Deol A et al. Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort. Bone Marrow Transplant 2015; 50: 432\u2013437.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201795","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.95","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T20:06:10Z","timestamp":1648065970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFbmt201795"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.95","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]},"assertion":[{"value":"31 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z Al-K has received a research grant support from Genzyme pharmaceuticals. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}